Hans Bitter

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Joseph A. Fraietta, Simon F. Lacey, Elena J. Orlando et al. · Nature Medicine · 2018 · 1.7K citations · Full text

T Cell Therapy, Cancer Immunosurveillance, Chronic Lymphocytic Leukemia +6

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

Hui Gao, Joshua M. Korn, Stéphane Ferretti et al. · Nature Medicine · 2015 · 1.4K citations

Tumor Biology, Radiology, Oncology +10

Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening

E. Robert McDonald, Antoine de Weck, Michael R. Schlabach et al. · Cell · 2017 · 687 citations · Full text

Bioinformatics, Tumor Biology, Radiation Oncology +13

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

Marco Ruella, Jun Xu, David M. Barrett et al. · Nature Medicine · 2018 · 620 citations · Full text

Autoimmune Disease, Immunology, Antigen Processing +5

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

Andrew A. Wylie, Joseph Schoepfer, Wolfgang Jahnke et al. · Nature · 2017 · 574 citations

Molecular Pharmacology, Drug Target, Medicine +3